Loading stock data…
Veradermics, Incorporated (MANE)
$123.58-3.31 (-2.61%)
Market ClosedLast close Jun 29
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | — | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.71M↓ | -$22.75M | — | -$12.88M↓ | -$5.58M |
| Net Income | -$27.23M↓ | -$21.85M | — | -$12.40M↓ | -$5.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The compan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.19%
Volume
Today's trading volume
645,359
Recent News
Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Veradermics (MANE) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Veradermics, Incorporated (MANE) A Good Stock To Buy Now?
Is MANE a good stock to buy? We came across a bullish thesis on Veradermics, Incorporated on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on MANE. Veradermics, Incorporated’s share was trading at $90.95 as of June 16th. Veradermics, Incorporated (MANE) is a clinical-stage biopharmaceutical company focused on developing innovative dermatology therapies targeting common […]
Viking Stake In Veradermics Highlights Risky Growth And Ownership Shifts
Viking Global Investors has disclosed a substantial beneficial ownership stake in Veradermics (NYSE:MANE) through several affiliated funds. The filing also reports a change in the reporting group, removing a previously named reporting person from the disclosure. This update clarifies how Viking’s exposure to Veradermics is structured and who is formally reporting that interest. For readers tracking NYSE:MANE, the involvement of a large institutional investor is often watched closely,...
Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026
Veradermics Inc. (NYSE:MANE) is one of the best performing NYSE stocks so far in 2026. On May 12, Veradermics reported a net loss of $27.2 million for Q1 2026, compared to a net loss of $12.4 million in the prior-year period. Driven by the late-stage clinical progress of its main pipeline asset, VDPHL01, R&D expenses […]
The IPO Boom Isn’t in Tech and AI—Yet
The ballyhooed debut of AI chip firm Cerebras is a big moment for tech IPOs. But don’t ignore new biotechs and industrial stocks.